Company Overview of Shionogi Pharma, Inc.
Shionogi Pharma, Inc. produces, markets, and sells branded prescription products focused on cardiovascular, diabetes, women's health, and pediatric treatment. It offers oral suspensions, tablets, and capsules, as well as products prescribed by the primary care physicians. The company provides cardiovascular and diabetes products that treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 diabetes; pediatrics products, which treat allergies, asthma, cough and cold, and attention deficit and hyperactivity disorders; and products for the health and well-being of women, as well as for mothers and their babies. It develops glycopyrrolate oral solution,...
Five Concourse Parkway
Atlanta, GA 30328
Founded in 1992
Key Executives for Shionogi Pharma, Inc.
Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2017.
Shionogi Pharma, Inc. Key Developments
Horizon Announces Proposes Private Offering of Senior Notes
Oct 13 16
Horizon Pharma plc announced that Horizon Pharma, Inc. and Horizon Pharma USA, Inc., its wholly owned subsidiaries, intend, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million aggregate principal amount of incremental term loans under Horizon’s existing senior secured credit facility. Horizon currently expects to use the net proceeds from the offering of notes and the incremental term loans to fund a portion of Horizon’s planned acquisition of Raptor Pharmaceutical Corp., repay Raptor’s outstanding debt, and pay any prepayment premiums, fees and expenses in connection with the foregoing. The notes and the incremental term loans will be fully and unconditionally guaranteed by Horizon, as well as by certain of its existing and future subsidiaries. The notes will be offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and to non-U.S. buyers in accordance with Regulation S under the Securities Act. The notes have not been and are not expected to be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
Shionogi Pharma, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-05-2016
Sep 28 16
Shionogi Pharma, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-05-2016. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Presentation Date & Speakers: Oct-05-2016, Joe Whalen, Senior Vice President, Business Development & Alliance Management.
Shionogi Pharma, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 02:00 PM
Jun 2 16
Shionogi Pharma, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|